J8560Etoposide oral 50 mg
Published CMS Medicare Part B payment-limit context for J8560, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$88.055
per 50 MG · Medicare Part B
Up 1.4%from $86.84 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$89.7759$74.0421
2024-Q4: $76.664; 2025-Q1: $76.524; 2025-Q2: $76.456; 2025-Q3: $75.763; 2025-Q4: $77.462; 2026-Q1: $86.79; 2026-Q2: $86.84; 2026-Q3: $88.055
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Etoposide ingredient family (FDA data as of August 20, 2026).
Etoposide
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Etoposide presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J9181 | Etoposide injection | $1.018 per 10 MG | $0.90 per 10 MG | Up 13.1% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.